Case Studies of FDA Submissions Leveraging Real-World Digital Health Data The integration of real-world data (RWD) and real-world evidence (RWE) in the regulatory framework has transformed the landscape of medical product development, especially in the realm of digital health. This tutorial provides a comprehensive overview and actionable insights into the case studies of FDA submissions that successfully leveraged RWD, emphasizing digital endpoints and their regulatory implications. Understanding Real-World Data and Real-World Evidence in FDA Submissions Real-world data refers to data relating to patient health status and the delivery of healthcare routinely collected from a variety of sources, such as electronic…

Regulatory Expectations for Validation of Digital Biomarkers and Endpoints The landscape of digital health is evolving rapidly, notably in the realms of digital biomarkers and digital endpoints. As regulatory bodies such as the FDA expand their guidelines, understanding the expectations for validation has become imperative for professionals working with Software as a Medical Device (SaMD), applications, and artificial intelligence solutions. This step-by-step tutorial outlines the essential components for validating digital biomarkers and endpoints while navigating the regulatory environment in the U.S., U.K., and E.U. Understanding Digital Biomarkers and Endpoints Digital biomarkers are objective, quantifiable physiological and behavioral data collected through…

Designing Virtual Studies that Generate RWD for Regulatory Grade Evidence Introduction to Real-World Data (RWD) and Real-World Evidence (RWE) In recent years, the importance of real-world data (RWD) and real-world evidence (RWE) has grown significantly within the realms of drug development and regulatory submissions. The United States Food and Drug Administration (FDA) recognizes RWD as data collected outside of traditional randomized clinical trials (RCTs), often gathered from various sources such as electronic health records, claims data, and patient registries. RWE, derived from RWD, refers to the clinical evidence pertaining to the usage and potential benefits or risks of a medical…

Strategies for Utilizing Real-World Data and Evidence in FDA Submissions for SaMD and Digital Therapeutics Introduction to Real-World Data (RWD) and Real-World Evidence (RWE) In recent years, the integration of Real-World Data (RWD) and Real-World Evidence (RWE) into regulatory submissions has gained significant traction, especially within the realms of Software as a Medical Device (SaMD) and digital therapeutics. The FDA describes RWD as data relating to patient health status and/or the delivery of healthcare that is routinely collected from various sources, which can include electronic health records, claims and billing activity, and data gathered through patient registries. RWE is derived…

Using Real World Data and Digital Endpoints in FDA Digital Health Submissions In the rapidly evolving landscape of digital health technologies, the integration of Real World Data (RWD) and Real World Evidence (RWE) has gained significant traction. With the U.S. Food and Drug Administration (FDA) paving the way in regulatory submissions, understanding how to effectively harness these components is critical for digital health, regulatory, clinical, and quality leaders involved with Software as a Medical Device (SaMD), applications, and artificial intelligence solutions. This tutorial offers a comprehensive, step-by-step guide on navigating FDA expectations for using RWD and digital endpoints in submissions….

Using Pragmatic Trials and Registries to Support Digital Health Labeling Introduction to Pragmatic Trials and Registries in Digital Health In the evolving landscape of digital health, the integration of real-world data (RWD) and real-world evidence (RWE) is becoming increasingly vital to support labeling claims and regulatory submissions. The U.S. Food and Drug Administration (FDA) has noted the importance of pragmatic trials and registries in generating meaningful clinical evidence through the use of digital health technologies. This tutorial will guide you through the steps necessary to utilize pragmatic studies and registries effectively in your regulatory strategy. Step 1: Understanding Real-World Data…

Statistical Methods Suited to RWE from Digital Health Deployments Introduction to Real-World Data and Real-World Evidence As the healthcare landscape evolves with the integration of digital technologies, the importance of real-world data (RWD) and real-world evidence (RWE) has surged. The FDA has underscored the potential of RWD and RWE in regulatory decision-making, particularly for the evaluation of medical devices, pharmaceuticals, and digital health solutions. This shift is particularly relevant for software as a medical device (SaMD), mobile health applications, and artificial intelligence (AI) solutions that impact clinical practice and patient management. RWD consists of data collected from various sources including…

Governance for RWD Curation and Analysis in Digital Health Companies In the evolving landscape of digital health, real-world data (RWD) and real-world evidence (RWE) have become pivotal in shaping regulatory strategies, clinical development pathways, and post-market assessments. Digital health companies focusing on software as a medical device (SaMD) must establish robust governance frameworks for the curation and analysis of RWD to effectively generate reliable digital endpoints for FDA submissions. This guide provides a step-by-step approach to creating this governance structure, ensuring compliance with FDA expectations while maximizing the potential of digital health innovations. Understanding Real-World Data and Evidence Real-world data…

Linking App Telemetry, Wearables, and EHR Data into Coherent RWD Packages As the digital health landscape continues to evolve, the integration of app telemetry, wearables, and electronic health records (EHR) data has become paramount for achieving meaningful insights and delivering substantial benefits to patients and healthcare systems. In the context of FDA regulations, leveraging real-world data (RWD) and real-world evidence (RWE) is critical for validating digital health tools and submitting successful applications for new software as a medical device (SaMD). This tutorial aims to provide a comprehensive, step-by-step guide on connecting these data sources into coherent RWD packages aligned with…

Data Quality and Provenance Considerations for RWE in Digital Health In the landscape of digital health, the integration of Real-World Data (RWD) and Real-World Evidence (RWE) has transformed how stakeholders approach medical decision-making, regulatory submissions, and the validation of digital endpoints. This article presents a comprehensive tutorial aimed at digital health, regulatory, clinical, and quality leaders seeking to understand how data quality and provenance impact FDA submissions involving RWD and RWE. Understanding Real-World Data and Real-World Evidence To effectively navigate the complexities of RWD and RWE, it is essential to establish a foundational understanding of these terms. RWD is defined…